Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...

Silence Therapeutics PLC ADR Annual stock financials by MarketWatch. View the latest SLN financial statements, income statements and financial ratios.

Silence Therapeutics plc (SLN) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Silence Therapeutics PLC Sponsored ADR (SLN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...

Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024. The 7 major polycythemia vera markets ...

Detailed price information for Silence Therapeutics Plc ADR (SLN-Q) from The Globe and Mail including charting and trades.

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces the ...

SLN is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of SLN shares has increased $0.08 since the market last closed. This is a 1.18% ...